ImmunityBio (NASDAQ:IBRX) stock faces July 24 warrant-expiry test after Friday rebound
ImmunityBio, Inc. enters next week with a warrant-expiry test. Up to 6.4 million new shares could emerge on Friday. That figure uses the March 31 balance.
ImmunityBio (NASDAQ:IBRX) trades after post-Russell spike with 46% more volume
ImmunityBio, Inc. goes into the week with a cleaner tape test despite what the price action shows. Shares were up 11.8% Friday, closing at $8.71. Trading volume topped 41.2 million shares, triple Google Finance’s average of 13.39 million. Market cap was close to $9.1 billion.
ImmunityBio (NASDAQ:IBRX) rises as Russell index rebalancing and high multiple draw buyers
ImmunityBio, Inc. shot higher Friday, sending its market cap well past the 2026 Russell large-cap threshold. Traders looking for index action piled into the biotech, which is already up more than four times since the start of the year.
ImmunityBio Faces FDA Decision on Bladder-Cancer Application, Risk Remains
ImmunityBio’s push to expand Anktiva’s use in bladder cancer is back before the FDA, after the agency accepted a supplemental biologics license application. The FDA set a target action date for Jan. 6, 2027. ImmunityBio wants approval for Anktiva used with Bacillus Calmette-Guérin, or BCG, for BCG-unresponsive non-muscle invasive bladder cancer patients with papillary disease and no carcinoma in situ.
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open
ImmunityBio shares were active before the Nasdaq bell on Monday after the company said five U.S. patents will protect its Anktiva-plus-BCG bladder cancer treatment into at least 2035. This statement followed Friday’s announcement of an exclusive U.S. supply deal with Japan BCG Laboratory. The stock last traded at $7.97, unchanged from Friday’s close, when it slipped 2.2% on volume of 11.3 million shares.
ImmunityBio (IBRX) Stock Tumbles After FDA Warning on Anktiva Claims
ImmunityBio was changing hands around $7.42 early Wednesday, matching Tuesday’s close after a sharp 21.1% drop sparked by an FDA warning letter that criticized the company for allegedly making false or misleading claims about its cancer therapy Anktiva. The shares had plunged as much as 26% during Tuesday’s trading.
ImmunityBio (IBRX) stock wobbles in premarket ahead of update call — what traders are watching
ImmunityBio slipped roughly 1.4% in premarket action Tuesday, trading at $10.29. Just a day earlier, the stock finished 6.75% higher at $10.44. Huge moves have marked recent sessions; shares have now soared over 400% year-to-date.
ImmunityBio stock jumps again in premarket as ANKTIVA sales surge puts IBRX in focus
ImmunityBio jumped roughly 3.5% to $11.95 before the bell Wednesday, tacking on to a swift two-day rally. Shares had finished Tuesday’s session up 17.5%, closing at $11.55.
ImmunityBio (IBRX) stock rises premarket after ANKTIVA sales surge, cash burn still in view
ImmunityBio shares ticked up roughly 1% to $8.70 before the bell Monday, following the company’s new update on ANKTIVA sales momentum.
ImmunityBio stock steadies near $7 after 15% jump; earnings next up
ImmunityBio, Inc. held steady at $6.93 in Tuesday’s premarket, following a big 14.6% jump to that same price on Monday.
ImmunityBio stock jumps into the weekend as IBRX traders eye an FDA resubmission clock
ImmunityBio shares ended Friday roughly 6% higher, closing at $6.25. That stands out as the S&P 500 tracker SPY dipped around 0.4%, and the Nasdaq 100 tracker QQQ dropped about 1.2%. The stock fluctuated between $5.68 and $6.45, with trading volume hitting close to 29.5 million shares.
ImmunityBio stock rebounds: FDA scrutiny, a $505 million note and the next catalyst for IBRX
ImmunityBio shares rose nearly 6% on Friday, clawing back from an early dip, as traders weighed fresh scrutiny tied to the drugmaker’s communications with the U.S. Food and Drug Administration. The stock was up 35 cents at $6.26, after trading between $5.68 and $6.45 on the day, on the Nasdaq.
ImmunityBio (IBRX) stock slips after SEC filing tweaks $505 million insider note — what traders watch next
ImmunityBio shares slipped 1.6% to $6.35 in late-morning trading Monday following news of an amendment to a sizable convertible note held by an affiliate of its executive chairman. The stock fluctuated between $6.28 and $6.92, with roughly 16.8 million shares changing hands.
ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday
ImmunityBio, Inc. shares closed Friday down 12.1% at $6.45, having traded as high as $7.88 and as low as $6.43 amid heavy volume.
ImmunityBio (IBRX) stock slides after glioblastoma update — here’s what investors watch next week
ImmunityBio shares closed Friday 12.1% lower at $6.45, after fluctuating between $7.86 and $6.44 during the session. The cancer immunotherapy firm saw roughly 76 million shares change hands.
ImmunityBio stock price swings as new glioblastoma data hits; IBRX traders eye Jan. 31 update
ImmunityBio shares jumped 2.7% to $7.54 in late morning trading Friday following new data on a chemo-free treatment for recurrent glioblastoma, a tough brain cancer. The stock fluctuated between $6.97 and $7.86, with over 31 million shares changing hands. Meanwhile, the SPDR S&P Biotech ETF slipped roughly 1.1%.
ImmunityBio (IBRX) stock rises before the bell after FDA talks point to new ANKTIVA filing
ImmunityBio shares climbed in premarket trading Thursday following the company’s announcement that U.S. regulators have specified the requirements for a new filing to expand the use of its bladder cancer treatment.
ImmunityBio stock price dips today as IBRX cools off after FDA resubmission update
ImmunityBio shares dropped roughly 2% to $6.35 in Wednesday afternoon trading, as investors pared back after the biotech’s recent regulatory update. The stock swung between $5.74 and $6.64, with around 67 million shares changing hands.
ImmunityBio (IBRX) stock slips premarket after FDA maps fresh ANKTIVA resubmission route in bladder cancer
ImmunityBio’s stock dropped 5.9% to $6.10 in premarket trading Wednesday. The move followed the company’s announcement of a meeting with the U.S. Food and Drug Administration to discuss a possible resubmission of its bladder-cancer treatment, ANKTIVA.
ImmunityBio (IBRX) stock jumps on FDA’s 30-day ANKTIVA resubmission path — what’s next
Shares of ImmunityBio, listed on Nasdaq, surged Tuesday following news that U.S. regulators outlined a potential path for the company to pursue an expanded bladder cancer indication for its drug ANKTIVA. The stock closed up 17.7% at $6.48, after trading between $4.94 and $7.97 on heavy volume.
TechStock² Updates
